Completed PHASE3 INTERVENTIONAL 2-arm NCT01712490

A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma

A Randomized, Open-label, Phase 3 Trial of A+AVD Versus ABVD as Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma

Sponsor: Seagen Inc.

Conditions Hodgkin Lymphoma

Interventions bleomycin brentuximab vedotin dacarbazine doxorubicin vinblastine

Updated 17 times since 2017 Last updated: Feb 12, 2026 Started: Nov 9, 2012 Primary completion: Apr 20, 2017 Completion: Feb 2, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Hodgkin Lymphoma and is currently completed. Seagen Inc. leads this study, which shows 17 recorded versions since 2012 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

17 versions recorded

Feb 2026 — Present [monthly]

Completed PHASE3

Status: Active Not Recruiting → Completed
Dec 2025 — Feb 2026 [monthly]

Active Not Recruiting PHASE3
Sep 2025 — Dec 2025 [monthly]

Active Not Recruiting PHASE3
Apr 2025 — Sep 2025 [monthly]

Active Not Recruiting PHASE3
Sep 2024 — Apr 2025 [monthly]

Active Not Recruiting PHASE3

▶ Show 12 earlier versions

Jul 2024 — Sep 2024 [monthly]

Active Not Recruiting PHASE3
Mar 2024 — Jul 2024 [monthly]

Active Not Recruiting PHASE3
May 2023 — Mar 2024 [monthly]

Active Not Recruiting PHASE3
Mar 2022 — May 2023 [monthly]

Active Not Recruiting PHASE3
Jan 2021 — Mar 2022 [monthly]

Active Not Recruiting PHASE3
Nov 2020 — Jan 2021 [monthly]

Active Not Recruiting PHASE3
Feb 2020 — Nov 2020 [monthly]

Active Not Recruiting PHASE3
Dec 2018 — Feb 2020 [monthly]

Active Not Recruiting PHASE3
Jun 2018 — Dec 2018 [monthly]

Active Not Recruiting PHASE3
Aug 2017 — Jun 2018 [monthly]

Active Not Recruiting PHASE3
Feb 2017 — Aug 2017 [monthly]

Active Not Recruiting PHASE3
Jan 2017 — Feb 2017 [monthly]

Active Not Recruiting PHASE3

First recorded

Nov 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Seagen Inc.
Takeda

Data source: Takeda

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aalborg, Denmark , Aarhus C, Denmark , Aberdeen, United Kingdom , Albany, United States , Albuquerque, United States , Alessandria, Italy , Ankara, Turkey (Türkiye) , Ann Arbor, United States , Antwerp, Belgium , Aoba-ku, Japan and 201 more locations